Ketrol

# Ketrol ## Overview - **Classification**: Non-steroidal Anti-inflammatory Drug (NSAID) - **Mechanism**: Reversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis for analgesic, anti-inflammatory, and antipyretic effects. ## Primary Indications 1. **Acute Moderate to Severe Pain** - Short-term management (up to 5 days). 2. **Post-operative Pain** - Reduction of opioid requirements. ## Adult Dosing ### Standard Dosing **Acute Moderate to Severe Pain** (Initial IV/IM) - **Dose**: **30 mg** IV or IM - **Frequency**: Every 6 hours - **Route**: Intravenous (IV), Intramuscular (IM) - **Maximum**: **120 mg/day** for IV/IM combination. - **Special Considerations**: A **60 mg single dose** IM may be given once. **Acute Moderate to Severe Pain** (Oral Maintenance after IV/IM) - **Dose**: **10 mg** - **Frequency**: Every 4-6 hours - **Route**: Oral (PO) - **Maximum**: **40 mg/day** (oral). - **Duration**: Total treatment (parenteral + oral) **not to exceed 5 days**. ### Dose Adjustments - **Renal Impairment**: * CrCl **30-50 mL/min**: Reduce dose by 50% (e.g., **15 mg** IV/IM q6h; Max **60 mg/day**). * CrCl **<30 mL/min**: **Contraindicated**. - **Hepatic Impairment**: No specific dose adjustment; use with caution. Monitor LFTs. - **Elderly Patients (≥65 years)**: * Start with lower end of dosing range: e.g., **15 mg** IV/IM q6h. * Higher risk of GI/renal side effects. Monitor closely. * Maximum daily dose for elderly: **60 mg/day**. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **Contraindicated**. - **Special Notes**: High risk of renal impairment, pulmonary hypertension, and necrotizing enterocolitis. Consider alternative analgesia. ### Infants (1-12 months) - **Dose**: **Generally not recommended** due to limited data and high risk of adverse effects. - **Special Notes**: Use **only if benefits outweigh risks** after specialist consultation. Closely monitor renal function, GI bleeding. ### Children (1-12 years) - **Indication**: Post-operative pain (select cases, hospital setting). - **Dose**: **0.5 mg/kg** IV or IM - **Frequency**: Every 6 hours - **Maximum**: **15 mg/dose** or **60 mg/day** (whichever is lower). - **Formulation**: IV/IM for acute pain. Oral liquid/crushed tablet if available for transition. - **Special Notes**: Total duration **not to exceed 5 days**. Monitor hydration, renal function. ### Adolescents (13-18 years) - **Dose**: May approach **adult dosing**, but start with lower end (e.g., **15 mg** IV/IM q6h). - **Frequency**: Every 6 hours - **Maximum**: **60 mg/day** IV/IM; **40 mg/day** PO. - **Special Notes**: Total duration **not to exceed 5 days**. Consider body weight. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to Ketrol or other NSAIDs (e.g., aspirin-exacerbated respiratory disease). - **Absolute**: Active gastrointestinal (GI) bleeding or peptic ulcer disease. - **Absolute**: Advanced renal impairment (CrCl <30 mL/min) or risk for renal failure. - **Absolute**: Coagulopathy or at high risk of bleeding (e.g., recent surgery, hemorrhagic stroke). - **Absolute**: Concurrent use with other NSAIDs or aspirin. - **Absolute**: As prophylactic analgesic before major surgery or during labor and delivery. - **Absolute**: Peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. ### Common Adverse Effects - **Very Common (>10%)**: Headache, nausea, dyspepsia, abdominal pain. - **Common (1-10%)**: Diarrhea, dizziness, edema, hypertension, elevated liver enzymes. - **Serious but Rare**: Gastrointestinal bleeding/perforation, acute renal failure, anaphylaxis, severe skin reactions (SJS/TEN), cardiovascular thrombotic events (MI, stroke). ### Key Drug Interactions - **Anticoagulants (Warfarin, Heparin)**: Increased risk of serious bleeding. **Avoid concurrent use**. - **Diuretics (Furosemide, Thiazides)**: Reduced diuretic effect, increased risk of renal impairment. **Monitor renal function and BP**. - **ACE Inhibitors/ARBs**: Reduced antihypertensive effect, increased risk of renal dysfunction. **Monitor BP and renal function closely**. - **Lithium**: Increased lithium levels, leading to toxicity. **Monitor lithium levels closely; adjust lithium dose as needed**. - **Methotrexate**: Increased methotrexate levels, leading to toxicity. **Avoid concurrent use or monitor closely and reduce methotrexate dose**. - **Other NSAIDs/Aspirin**: Increased risk of GI adverse effects. **Avoid concomitant use**. ## Monitoring & Follow-up - **Before Treatment**: Baseline renal function (SCr, CrCl), liver function tests (ALT/AST), complete blood count (platelets, Hgb). - **During Treatment**: * Monitor renal function (SCr, urine output) daily for IV/IM use, especially in at-risk patients (elderly, volume depleted). * Monitor for signs of GI bleeding (tarry stools, coffee-ground emesis, new abdominal pain). * Monitor blood pressure regularly. * Monitor for fluid retention/edema. - **Clinical Signs**: Watch for severe abdominal pain, black stools, decreased urine output, new or worsening swelling, or new onset/worsening hypertension. ## Clinical Pearls - 💡 **Short-Term Use**: Ketrol is for **short-term (≤5 days)** management of acute pain only due to significant GI, renal, and CV risks. - 💡 **Administer with Food**: Take oral Ketrol with food or milk to minimize gastrointestinal upset. - 💡 **Hydration is Key**: Ensure adequate hydration, especially in patients receiving IV/IM, to mitigate renal risk. - 💡 **Opioid-Sparing**: Can be effective in reducing opioid requirements, but does not replace them for very severe pain. - 💡 **Patient Counseling**: Counsel patients to report signs of bleeding (black stools), severe abdominal pain, or swelling immediately. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.